- 专利标题： ANTI-FC EPSILON-R1 ALPHA (FCER1A) ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND FCER1A AND CD3, AND USES THEREOF
-
申请号： US18153522申请日： 2023-01-12
-
公开(公告)号： US20230331845A1公开(公告)日： 2023-10-19
- 发明人: Jamie M. Orengo , Andre Limnander , Jee H. Kim , Andrew J. Murphy
- 申请人： REGENERON PHARMACEUTICALS, INC.
- 申请人地址： US NY TARRYTOWN
- 专利权人： REGENERON PHARMACEUTICALS, INC.
- 当前专利权人： REGENERON PHARMACEUTICALS, INC.
- 当前专利权人地址： US NY TARRYTOWN
- 分案原申请号： US16547910 2019.08.22
- 主分类号： C07K16/28
- IPC分类号： C07K16/28
摘要：
The present invention provides novel full-length human antibodies that bind to human Fc epsilon-R1 alpha (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both Fc epsilon-R1 alpha and CD3 and activate T cells via the CD3 complex in the presence of Fc epsilon-R1 alpha-expressing cells. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced Fc epsilon-R1 alpha-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of allergies, including anaphylaxis.
信息查询
